Study of EDK060 for adults with CMT1A
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new medicine called EDK060 for people with Charcot-Marie-Tooth disease type 1A (CMT1A). The study will check if the drug is safe and how the body processes it, with the goal of finding better treatments for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You need a confirmed diagnosis of CMT1A from a genetic test showing a PMP22 gene duplication.
- You should have some nerve activity in your arm or hand, measured by a nerve test.
- Your CMT1A symptom score must be between 2 and 20 on a standard scale.
- You must have weakness in lifting your foot (foot drop) in at least one leg.
- You cannot be pregnant, nursing, or planning to become pregnant, and you must use effective birth control if you could get pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
This trial looks for new markers of Charcot-Marie-Tooth 1A (CMT1A) early in the disease. Researchers hope to find signs that can help diagnose and track the disease better, which could lead to better treatments in the future.
This trial tests whether adding a special vibration device to an intensive rehab program helps improve balance in people with Charcot-Marie-Tooth disease type 1A. If you are between 18 and 65 and have mild to moderate leg weakness, you may be able to join.
This trial tests a gene therapy medicine (ELP-02) given through a spinal tap for children and young adults with a specific genetic form of CMT (CMT4J). It aims to slow or stop the disease from getting worse.
This study tests an experimental drug called PGN-EDODM1 for people with myotonic dystrophy type 1 (DM1). The goal is to see if it can help reduce symptoms like muscle stiffness (myotonia).
This study is looking for people with Charcot-Marie-Tooth disease (a nerve condition) and healthy volunteers to track long-term changes in the body. Researchers want to see if certain biomarkers (measurable signs) can help predict how CMT progresses over time.
Hear when a new Charcot-Marie-Tooth Disease Type 1A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.